Rituxan vs Ocrevus: The Off-Label MS Treatment Neurologists Keep Prescribing

Rituxan (rituximab) and Ocrevus (ocrelizumab) are both anti-CD20 monoclonal antibodies that deplete B cells, but only Ocrevus is FDA-approved for multiple sclerosis. Despite this, neurologists across the country routinely prescribe Rituxan off-label for MS — often because it costs a fraction of Ocrevus while appearing to produce comparable results. Understanding the trade-offs between these two closely related drugs is essential for anyone navigating this decision.

The Open Secret in Neurology

There is a conversation happening in neurology offices that rarely reaches the patient brochures. It goes something like this: Rituximab works just as well for MS as ocrelizumab, costs a quarter of the price, and has two decades of safety data. But it does not have the FDA stamp for MS, and that creates headaches with insurance.

This is not fringe thinking. Academic MS centers, including those at the University of Washington and Karolinska Institute in Sweden, have published extensively on rituximab for MS. Sweden, in fact, uses rituximab as the dominant B-cell therapy for MS, covering the vast majority of treated patients. The drug works. The question is why it does not have the indication — and how that absence affects patients.

The straightforward answer: Rituxan was originally developed for lymphoma and was later approved for rheumatoid arthritis and certain vasculitis conditions. By the time B-cell depletion emerged as a powerful MS strategy, Rituxan’s manufacturer had developed Ocrevus — a newer, patent-protected molecule — specifically for the MS market. There was no commercial incentive to fund the expensive phase III trials needed to get rituximab FDA-approved for MS.

How Rituxan and Ocrevus Compare Mechanistically

Both drugs are anti-CD20 monoclonal antibodies. They bind to the CD20 protein on B cells and trigger their destruction. The end result — near-complete B-cell depletion — is the same with both drugs.

The molecular differences:

• Rituximab is a chimeric antibody (part mouse, part human protein sequences)
• Ocrelizumab is a humanized antibody (more human, less mouse)

In theory, a more humanized antibody should trigger fewer infusion reactions and less anti-drug antibody formation. In practice, clinical experience suggests the difference is modest. Both drugs cause infusion reactions in a minority of patients, and both are well-tolerated overall.

Efficacy Evidence

Ocrevus earned its FDA approval based on the OPERA I and OPERA II trials (for relapsing MS) and the ORATORIO trial (for primary progressive MS). These were large, well-designed phase III studies.

Rituximab’s MS evidence comes from a different path:

• The HERMES trial (2008) showed rituximab significantly reduced relapses and MRI lesions in relapsing-remitting MS compared to placebo
• The OLYMPUS trial for primary progressive MS did not meet its primary endpoint, though subgroup analysis suggested benefit in younger patients with active inflammation
• Extensive real-world data from Sweden (over 6,000 MS patients on rituximab in the Swedish MS Registry) show relapse rates and disability progression comparable to what Ocrevus achieved in trials
• Multiple observational studies and meta-analyses have found no meaningful difference in efficacy between the two drugs for relapsing MS

The critical nuance: for primary progressive MS (PPMS), Ocrevus remains the only anti-CD20 therapy with a specific FDA approval and robust trial data. Rituximab’s evidence in PPMS is weaker, and some neurologists are less comfortable prescribing it off-label for this subtype.

The Cost Gap

This is where the conversation gets uncomfortable. The annual cost difference is stark:

With rituximab biosimilars now available, the cost advantage has widened further. For health systems, insurers, and patients — especially those with high-deductible plans or Medicare — the difference can be tens of thousands of dollars per year.

A practical detail worth knowing: because rituximab biosimilars are FDA-approved (for their on-label indications), some insurers are more willing to cover them off-label for MS than they are to cover brand-name Rituxan. This is a quirk of formulary design that patients and their neurology teams can sometimes leverage.

Insurance and Off-Label Complications

The biggest practical barrier to rituximab for MS is insurance approval. Because rituximab is not FDA-approved for MS, insurers can (and often do) deny coverage. This does not mean the drug is unavailable — it means the prescribing neurologist may need to:

• Submit documentation supporting off-label use, including published evidence and clinical rationale
• Go through peer-to-peer review with the insurer’s medical director
• File an appeal if initially denied

Some insurers, particularly certain state Medicaid programs and some Medicare Advantage plans, have actually started preferring rituximab for MS because of the cost savings. The landscape is uneven and changes frequently.

Meanwhile, Ocrevus benefits from being the FDA-approved option. Insurance coverage is generally smoother, prior authorizations are more straightforward, and the manufacturer’s copay program can bring out-of-pocket costs close to zero for commercially insured patients.

Side Effects and Safety

Because both drugs deplete B cells through the same mechanism, their safety profiles are largely overlapping:

• Infusion reactions: Both can cause reactions during or shortly after infusion. Pre-medication with corticosteroids and antihistamines is standard for both. Rituximab’s chimeric structure may slightly increase reaction risk, but this has not been a major differentiator in clinical practice.
• Infections: Both increase susceptibility to infections, particularly upper respiratory infections. The risk of serious infections, including PML, exists with both but remains rare.
• Hypogammaglobulinemia: Long-term B-cell depletion with either drug can lead to low immunoglobulin levels over years. Regular monitoring of IgG levels is recommended.
• Hepatitis B reactivation: Both require screening before initiation.

One area where rituximab has an advantage: length of safety record. Rituximab has been used since 1997 — nearly three decades of post-market surveillance data across oncology, rheumatology, and neurology. Ocrevus, approved in 2017, has a shorter track record. For patients and clinicians who value long-term safety data, rituximab’s extensive history is reassuring.

Quick Comparison Table

Which Patients Get Which Drug

In practice, the choice often depends less on medicine than on logistics:

• Patients with commercial insurance and good copay assistance: Ocrevus is often the path of least resistance. The manufacturer’s support programs frequently bring the cost to $0, and there are no off-label approval hurdles.
• Patients on Medicare or high-deductible plans: Rituximab’s lower list price can translate to meaningfully lower out-of-pocket costs, even with the off-label prescribing challenge.
• Patients in health systems that prefer rituximab: Some academic medical centers and VA hospitals have adopted rituximab as their default anti-CD20 for MS, based on cost-effectiveness analyses.
• Patients with PPMS: Ocrevus has the stronger evidence base and the FDA indication. Most neurologists default to Ocrevus here unless cost is prohibitive.
• Patients who value the longest safety track record: Rituximab’s nearly three decades of use across multiple diseases may provide additional peace of mind.

One uncomfortable truth: a patient’s drug should not depend on their insurance plan, but in the current system, it often does. A neurologist who is familiar with both options and willing to navigate insurance barriers gives patients the best chance of receiving the treatment that fits both their medical needs and financial reality. Patients who feel uncertain should ask their neurologist directly: “Would you consider rituximab for my MS, and if so, can your team help with the insurance process?”